
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp has demonstrated strong financial performance, with HEPLISAV-B sales increasing by 39% year-over-year in the fourth quarter of 2024, totaling $71.1 million, and a total FY24 revenue of $268.4 million, reflecting a 26% increase. The company's strategic positioning in the hepatitis B vaccination market, which is projected to exceed $900 million by 2030, along with an anticipated market share of at least 60%, underscores its potential for sustained growth. Additionally, Dynavax's commitment to a significant increase in its share repurchase program to $400 million indicates confidence in its financial health and future profitability.
Bears say
Dynavax Technologies Corp faces significant risks that contribute to a negative outlook on its stock. The company may encounter challenges in its clinical development pipeline, with potential failures to meet efficacy endpoints or adverse reactions that could hinder approval and commercialization. Additionally, Dynavax's reliance on limited revenue streams from its existing products, combined with ongoing regulatory and litigation risks, as well as a history of financial losses without a clear path to profitability, underscores concerns regarding its long-term viability in a competitive market.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares